Wholly Owned Pipeline

Wholly Owned Pipeline
2 | IPF | ~3M worldwide |
Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF). We are also exploring the potential evaluation of LYT-100 in radiation induced fibrosis, myocardial fibrosis and other organ system fibrosis based on the strength of existing data around the use of pirfenidone in these indications.
1 | Exploring additional indications (e.g., radiation induced fibrosis, myocardial fibrosis, other organ system fibrosis and lymphedema) |
Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF). We are also exploring the potential evaluation of LYT-100 in radiation induced fibrosis, myocardial fibrosis and other organ system fibrosis based on the strength of existing data around the use of pirfenidone in these indications.
1 | Solid tumors | >32K/year U.S. (Metastatic pancreatic cancer) |
Fully human monoclonal antibody designed to inhibit the activity of galectin-9, a key molecule expressed by tumors and immune cells and shown to suppress the immune system from recognizing and destroying cancer cells, which we are developing for difficult-to-treat cancer indications with poor survival rates, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and cholangiocarcinoma (CCA).
1 | Depression, anxiety & related indications |
Designed to unlock the validated efficacy of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need. Allopregnanolone, a positive allosteric modulator of GABAA receptors, has therapeutic potential across a wide range of neurological conditions like depression, epilepsy and other neurological and neuropsychological conditions, but has poor oral bioavailability as a result of first-pass liver metabolism. An intravenous formulation of allopregnanolone is approved by the FDA as a 60-hour infusion for the treatment of post-partum depression, though the method of administration has significant limitations.
Preclinical | Epilepsies & other neurological indications |
Therapeutic candidate designed to unlock the validated efficacy of cannabidiol (CBD). Derived from the Glyph platform, LYT-310 offers oral dosing and the potential for improved tolerability, which could expand the therapeutic application of CBD across a wider range of age groups and indications, including both rare and more common forms of epilepsy and other central nervous system disorders.
Phase completed | Phase in progress |
Preclinical, Research and Partnered Programs
Developing breakthrough medicines at PureTech

